<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36682572</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5492</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Transplant immunology</Title><ISOAbbreviation>Transpl Immunol</ISOAbbreviation></Journal><ArticleTitle>Rhinovirus/enterovirus identification by electron microscopy in lower respiratory tract infection in a patient with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation and donor lymphocyte infusion.</ArticleTitle><Pagination><StartPage>101792</StartPage><MedlinePgn>101792</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trim.2023.101792</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0966-3274(23)00009-6</ELocationID><Abstract><AbstractText>Donor lymphocyte infusion (DLI) is a curable treatment option, inducing a graft-versus-tumor effect in patients with relapsed hematological malignancies after allogeneic hematopoietic cell transplantation (allo-HCT). However, not only graft-versus-host disease but also pulmonary complications are problematic adverse events after DLI. Although viral infections can be associated with pulmonary complications after DLI, the mechanism underlying these complications remains unclear. Detecting the causative virus infections after pulmonary complications following DLI is challenging, as invasive examinations, such as bronchoalveolar lavage and lung biopsies, are necessary. Family Picornaviridae, including Human-Rhinovirus (HRV) and Enterovirus (EnV), can induce fatal lower respiratory tract infection (LRTI) in recipients who undergo allo-HCT, which can be underdiagnosed. We encountered a 62-year-old man with relapsed myelodysplastic syndrome 20 days after a second HLA-haplo-identical allo-HCT and 4 DLI procedures who was later found to have HRV and EnV LRTI by postmortem electron microscopy. Despite high-dose immunosuppression, severe hypoxemia did not improve, and he succumbed to respiratory failure. Immunosuppressive therapy for idiopathic pneumonia syndrome after allo-HCT may be effective, but its efficacy for acute respiratory failure after DLI is controversial. Our case indicated that the control of viral replication should be prioritized over that of inflammation in HRV and EnV LRTI after DLI.</AbstractText><CopyrightInformation>Copyright © 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Naonori</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan; Department of Hematology, Fuchu Hospital, Osaka, Japan. Electronic address: harada.naonori@omu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakaida</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan; Department of Pathology, Osaka City General Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukai</LastName><ForeName>Daiki</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan; Department of Hematology, Fuchu Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makuuchi</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Masatomo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takakuwa</LastName><ForeName>Teruhito</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimoto</LastName><ForeName>Mitsutaka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohsawa</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hino</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamae</LastName><ForeName>Hirohisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Transpl Immunol</MedlineTA><NlmUniqueID>9309923</NlmUniqueID><ISSNLinking>0966-3274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009190" MajorTopicYN="Y">Myelodysplastic Syndromes</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006086" MajorTopicYN="Y">Graft vs Host Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017710" MajorTopicYN="N">Lymphocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allogeneic hematopoietic cell transplantation</Keyword><Keyword MajorTopicYN="N">Donor lymphocyte infusion</Keyword><Keyword MajorTopicYN="N">Electron microscopy</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Rhinovirus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36682572</ArticleId><ArticleId IdType="doi">10.1016/j.trim.2023.101792</ArticleId><ArticleId IdType="pii">S0966-3274(23)00009-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle>